Decision Diagnostics Stock

Decision Diagnostics EBITDA per Employee

The EBITDA per Employee of Decision Diagnostics (DECN) as of Aug 10, 2026 is -420,286.40 USD. In the previous year, EBITDA per Employee was -258,876.40 USD — a change of 62.35% (lower).

EBITDA per Employee

-420,286.40USD

YoY

62.35%

Last updated:

EBITDA per Employee of Decision Diagnostics is 2026 -420,286.40 USD. EBITDA per Employee of Decision Diagnostics was 2025 -258,876.40 USD. It decreases by 62.35% lower compared to the previous year.
Access this data via the Eulerpool API

Decision Diagnostics Stock analysis

What does Decision Diagnostics do? The Decision Diagnostics Corp, founded in 2002, is a company specializing in the manufacturing of medical diagnostic test kits and devices. The company is headquartered in Westlake Village, California, and operates production facilities in various parts of the world. The company's history began when the founders recognized a need for reliable, affordable, and easy-to-use diagnostic devices. This realization led to the development of the first product, the Shasta GenStrip. This test strip allowed patients to monitor their blood sugar levels at home, thereby better managing their diabetes. Since then, Decision Diagnostics Corp has become a leading provider of diagnostic test kits and devices. The company has several divisions, including the pharmaceutical division, the medical division, and the consumables division. In the pharmaceutical division, the company develops and produces tests for the pharmaceutical industry. These tests are used to assess the efficacy of new drugs and detect side effects. The medical division, on the other hand, focuses on developing diagnostic devices for various applications. This includes a test for detecting cancer markers in the blood or a test for assessing vitamin D levels. Another important division of the company is the consumables division. Here, the company provides test strips, syringes, needles, and other materials needed in medical practices and hospitals. The business model of Decision Diagnostics Corp is based on the idea that every person has the right to reliable medical care. Therefore, the company is committed to developing diagnostic devices and test kits that are easy to use and affordable. This allows patients to independently monitor their condition at home and take quick action if necessary. An example of this is the Shasta GenStrip, the first test strip developed by the company. This test strip allows patients to measure their blood sugar at home and better manage their diabetes. The Shasta GenStrip is compatible with common blood glucose meters and is significantly cheaper than comparable products. Another product developed in the medical division is the eScreen. This device allows for quick and reliable testing of urine samples for drugs or alcohol. The eScreen is primarily used in occupational medicine to ensure that employees are not using drugs. Overall, Decision Diagnostics Corp has become an important player in the medical industry. The company strives to provide patients with access to high-quality and affordable diagnostic devices and test kits. Through the constant development of innovative products, the company contributes to improving medical care worldwide. Decision Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Decision Diagnostics stock

EBITDA per Employee of Decision Diagnostics is -420,286.40 USD in 2026.

EBITDA per Employee of Decision Diagnostics changed from -258,876.40 USD to -420,286.40 USD, representing a 62.35% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Decision Diagnostics since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Decision Diagnostics historically and in real time.

Access this data via the Eulerpool API

Workforce — Decision Diagnostics

All Key Metrics — Decision Diagnostics